Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

1.

The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease.

Ho JE, Scherzer R, Hecht FM, Maka K, Selby V, Martin JN, Ganz P, Deeks SG, Hsue PY.

AIDS. 2012 Jun 1;26(9):1115-20. doi: 10.1097/QAD.0b013e328352ce54.

PMID:
22382147
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals.

Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, Ganz P, Hsue PY.

AIDS. 2010 Jul 31;24(12):1897-905. doi: 10.1097/QAD.0b013e32833bee44.

PMID:
20543654
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.

Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, Xie Y, Martin JN, Ganz P, Deeks SG.

AIDS. 2009 Sep 24;23(15):2021-7. doi: 10.1097/QAD.0b013e32832e7140.

PMID:
19542863
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Li X, Margolick JB, Jamieson BD, Rinaldo CR, Phair JP, Jacobson LP.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):421-8. doi: 10.1097/QAI.0b013e31821e9f21.

PMID:
21602699
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group.

Arch Intern Med. 2003 Oct 13;163(18):2187-95.

PMID:
14557216
[PubMed - indexed for MEDLINE]
6.

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort.

J Antimicrob Chemother. 2007 Jun;59(6):1141-7. Epub 2007 Apr 13.

PMID:
17434879
[PubMed - indexed for MEDLINE]
Free Article
7.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team.

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249. Epub 2012 Jul 18.

PMID:
22805174
[PubMed - indexed for MEDLINE]
8.

A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R, Sinclair E, Palmer S, Martin JN, Busch MP, Deeks SG, Hsue PY.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):317-25. doi: 10.1097/QAI.0b013e31826e7d0f.

PMID:
22918156
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals.

Parikh RV, Scherzer R, Grunfeld C, Nitta EM, Leone A, Martin JN, Deeks SG, Ganz P, Hsue PY.

Atherosclerosis. 2013 Jul;229(1):246-52. doi: 10.1016/j.atherosclerosis.2013.04.025. Epub 2013 Apr 30.

PMID:
23711612
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals.

Manner IW, Trøseid M, Oektedalen O, Baekken M, Os I.

J Clin Hypertens (Greenwich). 2013 Feb;15(2):101-6. doi: 10.1111/jch.12029. Epub 2012 Oct 26.

PMID:
23339727
[PubMed - indexed for MEDLINE]
11.

Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy.

Mondy KE, de las Fuentes L, Waggoner A, Onen NF, Bopp CS, Lassa-Claxton S, Powderly WG, Dávila-Román V, Yarasheski KE.

AIDS. 2008 Apr 23;22(7):849-56. doi: 10.1097/QAD.0b013e3282f70694.

PMID:
18427203
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

PMID:
16941337
[PubMed - indexed for MEDLINE]
Free Article
13.

Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy.

Kulkarni H, Okulicz JF, Grandits G, Crum-Cianflone NF, Landrum ML, Hale B, Wortmann G, Tramont E, Polis M, Dolan M, Lifson AR, Agan BK, Ahuja SK, Marconi VC.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):387-95. doi: 10.1097/QAI.0b013e3182219113.

PMID:
21546844
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy.

Hileman CO, Longenecker CT, Carman TL, Milne GL, Labbato DE, Storer NJ, White CA, McComsey GA.

Antivir Ther. 2012;17(7):1345-9. doi: 10.3851/IMP2297. Epub 2012 Aug 9.

PMID:
22878464
[PubMed - indexed for MEDLINE]
15.

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.

Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.

Antivir Ther. 2010;15(2):165-75. doi: 10.3851/IMP1513.

PMID:
20386071
[PubMed - indexed for MEDLINE]
16.

Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ, Ahuja SK.

N Engl J Med. 2013 Jan 17;368(3):218-30. doi: 10.1056/NEJMoa1110187.

PMID:
23323898
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

[Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].

Pavie J, Porcher R, Fournier S, André F, Tournoux C, Palmer P, Rabian C, Jean-Michel M.

Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13. French.

PMID:
16025661
[PubMed - indexed for MEDLINE]
18.

Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.

Toulson AR, Harrigan R, Heath K, Yip B, Brumme ZL, Harris M, Hogg RS, Montaner JS.

J Infect Dis. 2005 Nov 15;192(10):1787-93. Epub 2005 Oct 5.

PMID:
16235178
[PubMed - indexed for MEDLINE]
Free Article
19.

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13.

PMID:
15167289
[PubMed - indexed for MEDLINE]
20.

Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.

Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study.

HIV Med. 2012 Jan;13(1):73-8. doi: 10.1111/j.1468-1293.2011.00956.x. Epub 2011 Nov 22.

PMID:
22106827
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk